Exova Group PLC Issue of Equity (9872P)
24 November 2016 - 8:00PM
UK Regulatory
TIDMEXO
RNS Number : 9872P
Exova Group PLC
24 November 2016
EXOVA GROUP PLC
ISSUE OF EQUITY
Exova Group plc (the "Company") announces that application has
been made to the UK Listing Authority and the London Stock Exchange
for a listing of 58,824 new ordinary shares of 1 pence each (the
"Shares") in the Company for admission on 28 November 2016 to
trading on the main market for listed securities of the London
Stock Exchange and to listing on the premium listing segment of the
Official List maintained by the Financial Conduct Authority. The
Shares will rank pari passu with the existing ordinary shares of
the Company.
The Shares were issued and allotted on 23 November 2016 to the
Exova Group Employee Benefit Trust to satisfy the exercise by Paul
Barry, a person discharging managerial responsibilities of the
Company ("PDMR"), of his fully-vested award under the Company's
Deferred Bonus Plan as set out in the Company's RNS announcement of
a dealing by a PDMR dated 24 November 2016.
Following the issue of the Shares, the number of ordinary shares
in issue will increase to 250,490,374. For the purposes of the
Financial Conduct Authority's Disclosure and Transparency Rules
("DTRs"), the issued ordinary share capital of the Company
following this allotment consists of 250,490,374 Shares with voting
rights attached (one vote per Share). There are no Shares held in
treasury. This total voting rights figure may be used by
shareholders as the denominator for the calculations by which they
will determine whether they are required to notify their interests
in, or a change to their interest in, the Company under the
DTRs.
For and on behalf of Exova Group plc
Date: 24 November 2016
Neil MacLennan
General Counsel & Company Secretary
Telephone: 0131 333 8053
About Exova
Exova is one of the world's leading laboratory-based testing
groups, trusted by organisations to test and advise on the safety,
quality and performance of their products and operations.
Headquartered in Edinburgh, UK, Exova operates 138 laboratories and
offices in 33 countries and employs more than 4,300 people
throughout Europe, the Americas, the Middle East, Asia/Asia Pacific
and Africa.
Exova's capabilities help to extend asset life, bring
predictability to applications, and shorten the time to market for
customers' products, processes and materials. With over 90 years'
experience, Exova specialises in testing across a number of key
sectors ranging from Aerospace to Fire & Building Products; Oil
& Gas and Industrials; Infrastructure & Environment;
Automotive; and Health Sciences.
This information is provided by RNS
The company news service from the London Stock Exchange
END
IOEBJBFTMBITBTF
(END) Dow Jones Newswires
November 24, 2016 04:00 ET (09:00 GMT)
Exova (LSE:EXO)
Historical Stock Chart
From Apr 2024 to May 2024
Exova (LSE:EXO)
Historical Stock Chart
From May 2023 to May 2024